From: Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease
Variable | Cases n = 1102 | Controls n = 444 | P- value |
---|---|---|---|
Age, years | 61.1 (10.1) | 59.7 (7.4) | <0.001 |
BMI, kg/m2 | 27.2 (3.7) | 26.7 (4.3) | 0.02 |
Sex, male % | 74.7 | 72.7 | 0.43 |
Current smoking, % | 27.3 | 11.0 | < 0.001 |
Diabetes mellitus, % | 21.6 | 3.7 | <0.001 |
Hypertension, % | 71.9 | 28.6 | <0.001 |
Family history of CAD, % | 38.2 | 20.1 | <0.001 |
Statins, % | 35.8 | 6.3 | < 0.001 |
ACE inhibitors, % | 47.8 | 8.3 | <0.001 |
Angiotensin receptor blockers, % | 5.0 | 3.8 | 0.327 |
Ejection fraction <40%#, % | 7.6 | - | - |
Hs-CRP*, mg/l# | 4.4 (1.9/12.4) | 1.5 (0.9/3.8) | <0.001 |
PLTP, U/l | 25.5 (9.8) | 22.4 (7.4) | <0.001 |
CETP, U/l | 49.9 (20.9) | 41.4 (17.4) | <0.001 |
Total cholesterol, mg/dl | 219.7 (45.7) | 238.4 (41.8) | <0.001 |
LDL cholesterol, mg/dl | 141.0 (40.1) | 155.5 (35.1) | <0.001 |
HDL cholesterol, mg/dl | 48.8 (14.7) | 59.4 (15.9) | <0.001 |
Triglyceride*, mg/dl | 141 (102/193) | 120 (87/167) | <0.001 |
Apolipoprotein A-I, g/l# | 1.31 (0.24) | 1.62 (0.28) | <0.001 |
Apolipoprotein B, g/l# | 1.20 (0.28) | 1.19 (0.23) | 0.3 |
Lipoprotein(a), mg/dl# | 36.3 (38.9) | 24.2 (30.4) | <0.001 |